Table S-3. SNP quality control.

	N, SNPs initially available	N, Excluded, could not map to hg19		N, Excluded, MAF < 0.15 (overall)	N, Excluded, non- autosomal	N, Excluded, call rate < 98% in cases and/or controls	HWE p < 10 ⁻⁵ in	N, remaining for final analysis
Allergic rhinitis	670,176	464	36,300	321,745	7,316	488	3,643	300,220
Asthma	670,176	464	36,300	321,745	7,316	305	3,385	300,661
Cardiac disease	670,176	464	36,300	321,745	7,316	325	3,210	300,816
Depression	670,176	464	36,300	321,745	7,316	463	3,694	300,194
Dermatophytosis	670,176	464	36,300	321,745	7,316	414	3,648	300,289
Diabetes, type 2	670,176	464	36,300	321,745	7,316	392	3,673	300,286
Dyslipidaemia	670,176	464	36,300	321,745	7,316	267	2,267	301,817
Hemorrhoids	670,176	464	36,300	321,745	7,316	348	3,583	300,420
Hypertensive disease	670,176	464	36,300	321,745	7,316	336	2,429	301,586
Osteoarthritis	670,176	464	36,300	321,745	7,316	259	2,788	301,304

N refers to number of SNPs. Quality control steps were applied sequentially, in the order indicated from left to right.